Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00519779
Other study ID # R21AT003912-01A1
Secondary ID AT003912
Status Completed
Phase Phase 2
First received August 21, 2007
Last updated March 22, 2012
Start date July 2007
Est. completion date December 2010

Study information

Verified date February 2012
Source National Center for Complementary and Integrative Health (NCCIH)
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardUnited States: Federal Government
Study type Interventional

Clinical Trial Summary

This study is designed to examine the effects of fish oil on immune function and mood in medical students.


Description:

This study will examine how supplementation with omega-3 polyunsaturated fatty acids (key fish oil components) affects immune and mood responses to examination stress. This study will examine these outcomes in medical students during academic examination periods as well as less stressful non-exam periods. Participants will take fish oil supplements or placebo pills for approximately 3 months during which time relevant mood, endocrine, and immune measures will be assessed.

For detailed information about the study, please visit our website at http://www.stressandhealth.org


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date December 2010
Est. primary completion date December 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- OSU preclinical medical or dental student, or graduate nursing student

- male or female

Exclusion Criteria:

- taking certain medications with immune or endocrine effects

- chronic health conditions

- smoking

- excessive use of alcohol or caffeine

- significant digestive problems

- routine use of fish oil or flaxseed supplements or high fish intake

- fish allergy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
omega-3 supplementation
2.5 g/day omega-3
Oral omega-3 fish oil placebo
to match experimental dosage

Locations

Country Name City State
United States The Ohio State University College of Medicine Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
National Center for Complementary and Integrative Health (NCCIH) Office of Dietary Supplements (ODS)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun. 2011 Nov;25(8):1725-34. doi: 10.1016/j.bbi.2011.07.229. Epub 20 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Serum ln(IL-6) log-transformed serum Interleukin-6 (IL-6)
Serum cytokine levels provide an assessment of systemic inflammation, the cytokine level circulating throughout the body. Higher levels are typically interrupted as worse unless an individual is acutely ill.
Stimulated cytokine production reflects the inflammatory cytokine production capacity of monocytes.
every 3 weeks for 3 months after initiating supplementation (outcome reported is the average outcome across all 4 time points) Yes
Primary Serum ln(TNF-a) log-transformed serum Tumor Necrosis Factor-alpha (TNF-alpha)
All cytokine measurements (e.g., IL-6 and TNF-a, serum and stimulated) were analyzed across time; however, no stress effects were found. Therefore, all assessments post-supplementation were averaged (time points 3-6) and analyzed to determine whether fish oil supplementation had an effect. Pooling these 4 assessments provides a better estimate of an individual's cytokine levels because single time point measurements can be affected by changes in exercise, alcohol consumption, or sleep in the preceding 24-48 hours.
every 3 weeks for 3 months after initiating supplementation (outcome reported is the average outcome across all 4 time points) Yes
Primary Stimulated ln(IL-6) log-transformed stimulated IL-6
Serum cytokine levels provide an assessment of systemic inflammation, the cytokine level circulating throughout the body. Higher levels are typically interrupted as worse unless an individual is acutely ill.
Stimulated cytokine production reflects the inflammatory cytokine production capacity of monocytes.
every 3 weeks for 3 months after initiating supplementation (outcome reported is the average outcome across all 4 time points) Yes
Primary Stimulated ln(TNF-alpha) log-transformed stimulated TNF-alpha every 3 weeks for 3 months after initiating supplementation (outcome reported is the average outcome across all 4 time points) Yes
Secondary ln(Beck Anxiety Score) log-transformed Beck anxiety score, min-max values - 0-4.1: higher means greater anxiety every 3 weeks for 3 months after initiating supplementation (outcome reported is the average outcome across all 4 time points) No
Secondary ln(CES-D) log-transformed Center for Epidemiologic Studies Depression Scale (CES-D) score
The CES-D is a self-report scale designed to measure current symptoms of depression rated on a four-point likert scale.
Scores range from 0-60, with higher scores indicating a higher frequency of depressive symptoms.
every 3 weeks for 3 months after initiating supplementation (outcome reported is the average outcome across all 4 time points) No